Current Report Filing (8-k)
22 Septembre 2017 - 10:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 18, 2017
BIOSCRIP, INC.
(Exact name of Registrant as specified in
its charter)
Delaware
|
|
001-11993
|
|
05-0489664
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1600 Broadway, Suite 700, Denver, Colorado
|
|
80202
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (914) 460-1600
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported by BioScrip, Inc. (the “Company”),
C. Britt Jeffcoat and the Company agreed that he would step down from his position as Vice President, Controller and Chief Accounting
Officer of the Company. Mr. Jeffcoat’s last day with the Company was September 22, 2017.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
Date: September 22, 2017
|
|
/s/ Kathryn Stalmack
|
|
By:
|
Kathryn Stalmack
|
|
|
Senior Vice President, General Counsel and Secretary
|
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about BioPlus Acquisition Corporation (NASDAQ): 0 recent articles
Plus d'articles sur Bioscrip, Inc.